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Breast Cancer (BC) is one of the most commonly diagnosed malignancies in females. The 5-year 
survival rate for women with early stage BC is about 90%. However, the quality of life (QOL) 
for many of these women may be adversely affected due to treatment/cancer–related side effects, 
including a constellation of symptoms (anxiety, depression, pain, fatigue, sleep disturbance and 
depression), that are collectively termed psychoneurological symptoms (PNS). To gain insight 
into the contributory role of telomere length (TL) in the development and persistence of PNS, we 
have longitudinally studied 72 women (ages 23-71) with early stage BC (I-IIIA) at 5 time points: 
prior to chemotherapy (baseline), prior to the fourth cycle of chemotherapy (mid-chemo), 6 
	   ix	  
months, 1 year and 2 years following the initiation of chemotherapy. Measures quantified 
included TL [using both a monochrome multiplex qPCR assay (at 5 time points) and a semi-
quantitative chromosome-specific fluorescence in situ hybridization (FISH) assay (at baseline 
and mid-chemo)] and scores for each PNS. Variables predictive of qPCR mean TLs were age 
(p=0.004) and race (African Americans had greater mean TLs than Caucasians; p=0.019). While 
visit was not found to be a significant predictor of mean TLs (p=0.666), chromosome-specific 
TL shortening was observed at mid-chemo for 1p (p =0.022), 5q (p = 0.041), 7q (p =0.025), 9q 
(p =0.045), 18q (p =0.002), 20p (p =0.020), 21q (p =0.040) and 22p (p =0.025). Type of 
chemotherapy was shown to be a significant predictor of both mean TLs (TAC significantly 
greater than TCH; p= 0.036) and chromosome-specific TLs for 32 of the 46 chromosomal arms 
(p=0.004 to 0.049). Pain was found to be a significant negative predictor of chromosome-
specific TLs (higher pain; shorter telomeres) for 5q (p=0.040), 8p (p=0.047), 13p (p=0.019), 20p 
(p=0.036), 22p (p=0.035), Xp (p=0.014), Xq (p=0.039). Expanding upon the knowledge gained 
from this study offers hope for the future development of biomarkers that could identify patients 
at risk for PNS and improve their QOL.
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Chapter 1 
General Background 
Breakthroughs in Early Telomere Research  
      Telomeres were first described in the 1930s by Hermann Muller and Barbara McClintock, 
through their studies in Drosophila (Muller, 1938) and maize (McClintok, 1941), as special 
structures at the end of chromosomes required for their integrity. Muller first coined the term 
“telomere” and three years later, McClintock (1941) proposed that telomeres stabilize 
chromosome ends and prevent them from being recognized as DNA double strand breaks.  
      In 1961, Leonard Hayflick and Paul Moorhead developed a theory that cells cultured in vitro 
were not immortal, but could replicate only a finite number of times, a phenomenon now known 
as replicative senescence or the the “Hayflick limit”, and suggested the existence of a cellular 
counting mechanism (Hayflick & Moorhead, 1961). Furthermore, they observed the presence of 
two broad classes of cells, normal mortal cell strains and immortal cancer cell lines (reviewed in 
Hayflick, 1998). Their discovery challenged a central dogma of the time that supported the belief 
that cultured cells would divide indefinitely in vitro, with any culture failures being attributable 
simply to a lack of technical expertise.  
      Fast forwarding to the 1970s, James Watson described the cell’s inability to replicate up to 
the tip of the chromosome as the “end replication problem” (Watson, 1972). By combining the 
knowledge that the properties of DNA polymerase prevent cells from fully replicating the ends 
of linear chromosomes with the observation that normal cells have a limited capacity to replicate, 
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Olovnikov, was the first to suggest that chromosomal shortening may be linked to a cell’s 
eventual mortality (Olovnikov, 1973). It has been reported that Olovnikov developed this 
hypothesis while waiting for a subway train in Moscow. As he heard the train coming, he 
imagined the train, and specifically the engine, being the DNA polymerase and the track being 
the DNA. The engine (DNA polymerase) would not be able to replicate the first segment of 
DNA (the track) because it lays exactly underneath the engine. It seemed unlikely that with each 
cell division a DNA segment containing important genes was lost. Therefore, Olovnikov 
reasoned that the repeated non-coding telomeric nucleotide sequences act as a buffer to protect 
gene coding sequences. He correctly speculated that with each round of cell division a portion of 
the telomere “buffer” would be lost, and that the length of the telomeric “buffer” could be 
important for determining a cell’s ability to proliferate (reviewed in Hayflick, 1998; Greider, 
1998).  
      In 2009 the Nobel Prize in Medicine or Physiology was jointly awarded to Elizabeth 
Blackburn, Carol Greider and Jack Szostak for elucidating the structure and maintenance of 
telomeres. The work leading to this prize dates back to 1978 when Blackburn, together with her 
mentor Joseph Gal discovered the telomere’s DNA sequence (Blackburn & Gall, 1978). In 
collaboration with Jack Szostak, Blackburn published evidence for the evolutionary conservation 
of telomeres and their role in providing chromosomal stability (Szostak & Blackburn, 1982). 
Furthermore, insight to the regulation of telomere length was gained by Greider and Blackburn 
in 1983 by discovering enzymatic activity in Tetrahynema cell extracts that compensated the 
incomplete replication in telomere ends (Greider & Blackburn, 1985). They subsequently 
purified the enzyme and found it to be a ribonucleoprotein (RNP) that was comprised of an RNA 
component, as well as a protein component. Thus, they had discovered a new type of DNA 
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polymerase, which they named “telomerase” (Greider & Blackburn, 1987). Moreover, they 
discovered that the RNA component contained the template required for the addition of 
nucleotide repeats onto telomeres. Although all of these findings were in Tetrahymena, it is now 
known that telomerase provides the main mechanism by which telomeres are elongated in 
eukaryotes. Taken together, these discoveries were the foundation for the importance of telomere 
biology in normal aging and in pathology.  
Structure of the Telomeric Region  
      As a result of intensive research that has been completed since these pioneering studies, 
much is now known about the telomeres. In humans, telomeres are stretches of non-coding 
tandemly repeated “TTAGGG” DNA sequences that can reach a length of 15,000 base pairs. 
They are located at the terminal ends of all vertebrate chromosomes, including those of humans 
(Moyzis et al., 1988). Approximately 50-300 base pairs of single stranded DNA that is G-rich 
extends from the 3’ strand forming an overhang that is thought to be important for telomere 
function (Makarov et al., 1997, Wright et al., 1997). This single stranded 3’ overhang folds back 
on itself forming a large loop structure called a telomere loop or T-loop, that has a shape similar 
to that of a paper clip, and invades an upstream telomeric double stranded DNA forming a 
displacement loop or D-loop. 
      Telomere stabilization and maintenance relies on a six-protein complex called shelterin, 
which is composed of telomeric repeat binding factor 1 and 2 (TRF1 and TRF2), the human 
ortholog of the yeast repressor/activator protein 1 (Rap1), TRF1 interacting nuclear factor 2 
(TIN2), protection of telomerase 1 (POT1) and TPP1. Shelterin components specifically localize 
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to the telomere due to the recognition of the duplex part by TRF1 and TRF2 and their interacting 
proteins Rap1 and TIN2, whereas POT1 forms a heterodimer with TPP1 and recognizes the G-
strand overhang. These protein-DNA and protein-protein interactions are responsible for 
maintaining telomere homeostasis (Palm & de Lange, 2008).  
      The chromatin structure of mammalian telomeres has properties that are characteristic of 
heterochromatin. In particular, trimethylation of histone H3 lysine 9 (H3K9) and histone H4 
lysine 20 (H4K20) are observed in telomeric and sub-telomeric regions (reviewed in Blasco, 
2007). In addition, these regions are enriched in heterochromatin protein 1 (HP1), which is 
important for chromatin compaction (reviewed in Blasco, 2007). Another mark of 
heterochromatin that is present in telomeric and sub-telomeric regions is low levels of acetylated 
H3 (AcH3) and H4 (AcH4) (reviewed in Blasco, 2007). Also, akin to heterochromatic regions, 
the sub-telomeric regions are gene-poor, and the telomeric regions do not contain any genes 
(reviewed in Blasco, 2007).  
Telomere Functions  
      The telomere serves to cap chromosome ends and maintain genomic stability through various 
mechanisms. One function is to prevent chromosomal ends from being distinguished as DNA 
double strand breaks; thereby avoiding the activation of DNA damage signaling pathways and 
genome instability (de Lange, 2009). Ataxia telangiectasia mutated (ATM) kinase pathway and 
ataxia telangiectasia and Rad3 related (ATR) kinase pathway are activated in mammalian cells in 
response to DNA double and single strand breaks in order to arrest the cell cycle and/or induce 
apoptosis (programmed cell death). Moreover, homology directed repair (HDR) and non-
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homologous end joining (NHEJ) repair pathways can also be activated to ensure that cells 
continue dividing with an intact genome. Telomeres, along with the shelterin complex, offsets 
the effect of these four “repair” processes. Specifically, the TRF2 subunit of shelterin is 
responsible for ensuring that the ATM kinase signaling pathway and NHEJ repair pathway are 
not activated by formation of the T-loop. The POT1 subunit is responsible for repressing the 
ATR kinase signaling pathway by preventing RPA, the single stranded DNA binding protein, 
from binding to the telomeric single stranded DNA. Both TRF2 and POT1 block the activation 
of the HDR pathway. Failure to do so causes cell cycle arrest under the direction of: a) ATM 
and/or ATR; b) chromosome end-to-end fusion mediated by NHEJ; or c) sequence exchange by 
HDR involving two telomeres or a telomere and another part of the genome (de Lange, 2002, 
d’Adda di Fagagna et al., 2003, Bailey & Murnane, 2006).  
      Due to the inherent inability of the DNA machinery to fully replicate the end of linear 
chromosomes, successive cell division leads to attrition of chromosome ends. Given that, 
telomeres are capable of averting the end replication problem and avoiding the loss of valuable 
genetic information by the presence of the cellular ribonucleoprotein enzyme telomerase, which 
can add telomeric repeat sequences to the end of chromosomes (de Lange, 2009). Additionally, 
telomere attrition can be compensated for through a recombination based telomerase-
independent mechanism termed alternative lengthening of telomeres (ALT) (Xu et al., 2013).  
Regulation of Telomere Length  
      In humans, telomere length is maintained by the the enzyme telomerase, which is composed 
of a reverse transcriptase protein (TERT) consisting of 1132 amino acids encoded by the hTERT 
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gene, which is located on the short arm of chromosome 5 (5p15.33). Additionally, it is composed 
of telomerase RNA component containing 451 nucleotides, which is encoded by the telomerase 
RNA gene hTERC, which is located on the long arm of chromosome 3 (3q21-q28) (reviewed in 
Aubert & Lansdorp, 2008). TERT uses the telomerase RNA component (that is complementary 
to the telomere sequence) as a template for telomere repeat synthesis at the 3’ overhang. 
Although telomerase is expressed during development, post-neonatal somatic cells repress 
telomerase expression except in germ cells, stem cells and a subset of somatic cells (such as 
active fibroblasts). Most neoplastic cells derepress the expression of hTERT to allow for 
immortalization and tumor formation (reviewed in Cesare & Reddel, 2008).   
      As stated above, elongation of telomeres in cells not depending on telomerase is called ALT.  
To date, most of the molecular details in ALT pathways remain unknown and very little is 
known regarding the mechanism(s) by which this pathway is activated. Current findings suggest 
that this process relies on homologous recombination between individual telomeres, where one 
telomere serves as a template for recombination-based elongation of another telomere (Gocha et 
al., 2013).  
Telomere Shortening, Aging, and Disease  
      A lack of telomerase activity in the majority of normal cells is associated with the end 
replication problem resulting in the loss of 50-100 base pairs at the telomeric end after each 
round of cell division (Oeseburg & de Boer, 2010). This mechanism functions as a biological 
clock to eliminate cells that have lived too long or long enough to accumulate aberrations and 
mutations. Following approximately 50-70 cell doublings, gradual telomere shortening 
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eventually results in critically short telomeres, leading to the activation of a DNA damage 
response (DDR) and the cell enters a state of permanent growth arrest (senescence) or apoptosis 
(Oeseburg & de Boer, 2010).  
      In humans, twin studies have concluded that telomere length is highly heritable, with 
inheritance estimates ranging from 40% up to 80% (Slagboom et al., 1994, Vasa-Nicotera et al., 
2005, Andrew et al., 2006, Najajou et al., 2007). While genetic determination of telomere length 
was thought to be X-linked, current evidence suggests paternal inheritance (Nawrot et al., 2004, 
Nordfjall et al., 2005). At birth, one study found no difference in telomere length between sexes 
in newborn (Okuda et al., 2002). Another study found that female newborns have longer 
telomere lengths than males (Aubert et al., 2012). Moreover, adult males have been found to 
have shorter telomere lengths than adult females suggesting an influence of environmental 
factors and/or estrogen (Okuda et al., 2002, Hunt et al., 2008). Racial differences have also been 
found to impact telomere length. In newborns as well as in adults, African-Americans have been 
reported to have longer telomeres than Caucasians (Zanni & Wick, 2011, Drury et al., 2015).                     
      Telomere attrition is one of the well-known cell intrinsic events associated with normal 
cellular aging, both directly and indirectly. Cellular senescence is defined as a state where the 
cell is unable to proliferate even with the availability of nutrients and mitogens (Campisi & 
d’Adda di Fagagna, 2007). Given that aging is characterized by an increase in senescent cells in 
many tissues and the observation of an inverse relationship between age and telomere length, 
replicative senescence induced directly through telomere shortening is involved in the aging 
process by limiting tissue renewal and influencing tissue homeostasis (Shay & Wright, 2005). 
Although the physiological role of senescent cells is still poorly understood, these cells secrete 
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pro-inflammatory cytokines, thereby negatively affecting the tissue microenvironment and 
function (Collado, Blasco & Serrano, 2007).   
      In addition, oxidative stress has been implicated in triggering cellular senescence. Harman’s 
“free radical theory” is one of the oldest of current theories suggesting that damage to cellular 
macromolecules via free radicals is a major determinant of life span. Oxidative stress can be 
defined as the net result of an imbalance between production and destruction of reactive oxygen 
species (ROS) (reviewed in Kregel and Zhang, 2007). Because of it’s high content of guanine 
bases, telomeric DNA is chemically more prone to oxidative damage, which, in turn, accelerates 
telomere shortening (reviewed in Blackburn, Epil & Lin, 2015). Therefore, the notion of 
telomeres acting as a cumulative measure of oxidative stress suggests an indirect involvement of 
accelerated telomere attrition with normal cellular aging.  
            More importantly, telomere attrition and dysfunction have been shown to be a causal 
factor in the acquisition of age-related diseases, including but not limited to atherosclerosis 
(Bentos et al., 2004, de Beer et al., 2015); myocardial infarction (Brouilette et al., 2003, D’Mello 
et al., 2016); Alzheimer’s dementia (Panossian et al., 2003, Guan et al., 2013); and heart failure 
(reviewed in Oeseburg., 2010). Accelerated telomere shortening has also been associated with a 
wide array of lifestyle factors such as smoking, consumption of unhealthy diet, obesity and lack 
of exercise (reviewed in Shammas, 2011). Furthermore, telomeres are implicated in cancer 
biology, due to their stabilizing effect on the chromosome and association with cellular 
proliferation (de Lange, 2005, Xu et al., 2013). The progression from a normal cell to a cancer 
cell occurs through a number of effects in which the cell acquires the so-called “hallmarks of 
cancer” (Hanahan & Weinberg, 2000). Replicative telomere attrition is considered one of several 
	  
	   9	  
regulatory mechanisms that blocks cell immortality, which is considered as one of the hallmarks 
of cancer cells (reviewed in Xu et al., 2013).  Replicative senescence occurs in a cell following 
the activation of ATM and ATR signaling pathways and the associated downstream factors 
including CHK1, CHK2, and phosphorylation of p53 and results in a cell cycle arrest in Gap 1 
(G1) phase of the cell cycle, thereby inhibiting tumorigenesis (reviewed in Raynaud et al., 2008). 
However, a DNA damage checkpoint deficient cell can continue dividing through p53 or pRb 
inactivation, resulting in extensive telomere attrition. As a result, telomeres lose their protective 
function, thereby allowing frequent chromosomal fusions and rearrangements, which, in turn, 
leads to massive genomic instability, the latter of which can promote carcinogenesis. In addition, 
cell death is bypassed and immortality is achieved by telomere length maintenance through the 
up-regulation of telomerase in > 85% of human tumors (Raynaud et al., 2008). In the remaining 
~15% of human tumors, telomere length is maintained by ALT (reviewed in Cesare & Reddel, 
2008).    
Impact of Environmental Factors on Telomere Length  
      Variation in the rate of biological aging reflects the accumulative burden of genetic, 
metabolic and environmental stressors, resulting in oxidative damage and elevated inflammatory 
processes (Lamb and Shiels, 2009). Stress results in the activation of the hypothalamic pituitary 
adrenal (HPA) axis and the release of glucocorticoid hormones by the adrenal glands. These 
hormones have been associated with reduced antioxidant capacity that may therefore cause 
increased oxidative damage to the DNA and accelerate telomere shortening (Patel et al., 2002, 
von Zglinicki, 2002, Irie at al., 2003). Telomere length have also been linked with various 
psychological conditions (Lindqvist et al., 2015). Shorter telomere length has also been linked 
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with longer duration of chronic stress (mothers caring for chronically ill children) in comparison 
to mothers caring for healthy children with a difference equivalent to 10 years of life between the 
two groups (Epel et al., 2004). Based on this observation, it could be hypothesized that women 
under stress were at an increased risk of developing age-related health problems. In a similar 
study, investigators reported higher depressive symptoms and shorter telomere lengths among 
caregivers of patients with Alzheimer disease compared to gender and age-matched controls 
(Damjanovic et al., 2007).  
      Beside psychological conditions, lifestyle behaviors have also been shown to impact 
telomere length. Smoking is associated with accelerated telomere attrition through the increase in 
oxidative stress with a pack of cigarettes a day for a period of 40 years being equivalent to 7.4 
years of life (Valdes et al., 2005, Song et al., 2010, Babizhayev et al., 2011). Obesity also has a 
negative impact on telomere length through obesity-related oxidative damage and the 
deregulated production of adipocytokines (Valdes et al., 2005, Song et al., 2010). Exposure to 
genotoxic agents that cause damage to the DNA and its association with telomere length have 
also been evaluated. Chemotherapeutic drugs have been shown to have a negative impact on 
telomere length by means of oxidative stress and uncapping telomeres (Lu et al., 2013, Liu, 
Hales and Robaire, 2014). Radiation-induced telomere dysfunction has also been reported by 
causing DNA double strand breaks, which are inefficiently repaired at the telomere or by 
telomere uncapping in human cancers (Li et al., 2012, Mirjolet et al., 2015). However, the effect 
of radiation on telomere dynamics has not been thoroughly studied. Investigators showed shorter 
telomere length in traffic police officers exposed to toluene and benzene pollution, relative to 
telomere length in office police workers (Hoxha et al., 2009). Similarly, significantly increased 
chromosomal instability and shorter telomere length have been noted in coke-oven workers 
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exposed to polycyclic aromatic hydrocarbons, relative to matched controls (Pavanello et al., 
2010). Furthermore, lower socio-economic status is associated with a decline in telomere length. 
It is assumed that low income increases the likelihood of being on a poor quality diet, fat and 
sugar rich, which are known to result in the production of more ROS(s) that directly causes DNA 
breaks (Saretzki & VonZglinicki, 2002, Sheils et al., 2011). Also, the results of several studies 
support associations of short sleep duration and poor quality sleep with shorter leukocyte 
telomere length (Prather et al., 2015, reviewed in Tempaku, Mazzotti & Tufik, 2015).  
      In contrast, healthy lifestyle behaviors that decrease oxidative stress and inflammation have 
been shown to preserve telomere length and reduce the pace of aging. Telomere length correlates 
positively with the increased dietary intake of fiber (Cassidy et al., 2010). Moreover, a diet rich 
in antioxidants, particularly, omega 3 fatty-acids is associated with reduced rate of telomere 
shortening in participants of a study over a period of 5 years (Farzaneh-Far et al., 2010). In 
addition, longer periods of physical activity and intensive sports have been associated with 
longer leukocyte telomere lengths especially among older adults (Sabenroth et al., 2015, Soares-
Miranda et al., 2015). A study in 2,401 healthy twins has shown that physically active 
participants have longer leukocyte telomere length when compared with their age and gender-
matched non-exercisers (Cherkas et al., 2008). Psychosocial stress reduction through 
mindfulness meditation was not only found to increase telomerase activity in peripheral blood 
mononuclear cells but also lengthen telomeres (Schutte & Malouff, 2014, Carlson et al., 2015).    
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Telomere Length Measuring Techniques 
      There is a large and rapidly growing body of data showing the implication of telomere 
biology in aging and disease processes.  Indeed, telomere lengths have emerged as a potential 
biomarker for risk assessment of diverse health outcomes (Fossel, 2012). The “gold standard” 
method for measuring telomere length is the terminal restriction fragment (TRF) technique by 
southern blot (Southern, 1979). Genomic DNA is typically digested using a cocktail of 4-6 
restriction enzymes that lack recognition sites in telomeric and subtelomeric regions. The intact 
telomere fragments are then visualized and size estimated via gel electrophoresis. In addition to 
providing only an average of total telomere lengths, shortcomings of this assay include the need 
for large amounts of DNA (micrograms), as well as the technique being labor intensive. Also, 
inclusion of subtelomeric regions in this assay, due to the nature of the restriction enzymes used, 
can provide an overestimation of the true telomere length (reviewed in Montpetit et al., 2014).     
      Polymerase Chain Reaction (PCR)-based techniques have also been used in measuring 
telomere length by amplifying both telomere repeats and a single copy housekeeping gene(s) 
(Cawthon, 2002, Cawthon, 2009). Calculating the ratio between the two quantities yields a 
measure of relative telomere length (Cawthon, 2002, Cawthon, 2009). PCR-based methods 
include quantitative PCR (qPCR), monochrome multiplex qPCR (MMqPCR), and absolute 
telomere length (aTL) qPCR. Unlike the TRF assay, PCR- based telomere measuring assays 
require small amounts of DNA (nanograms) and are considered high-throughput assays of 
relatively low cost. However, like TRF, PCR-based methodologies do not provide information 
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on telomere length at individual chromosome ends; hence they do not allow for the recognition 
of specific chromosomes with short and/or dysfunctional telomeres (reviewed in Vera & Blasco, 
2012).  
       Single telomere length analysis (STELA) is a telomere measuring assay that overcomes the 
limitations of TRF and qPCR based methods by providing a length for specific individual 
chromosomes (Baird et al., 2003). STELA is a qPCR-based technique that is designed to amplify 
the telomeric DNA of a single chromosome, using primers that are specific for the sub-telomeric 
sequence of that chromosome. Measuring telomere lengths on individual chromosomes is of 
great importance since a single or a small number of short telomere(s) has (have) been suggested 
to initiate a DNA damage response leading to senescence or apoptosis (Hemann et al., 2001, 
Abdallah et al., 2009). Unfortunately, to date, telomeres of only a subset of chromosomes (Xp, 
Yp, 2p, 11q, 12q, and 17p) can be measured through this technique due to the lack in specificity 
of sub-telomeric regions between chromosomes. Another major disadvantage of this technique is 
its limited ability for the analysis of very long telomeres (reviewed in Montpetit et al., 2014).          
      One of the most accurate telomere measuring methods is the Quantitative Fluorescence In 
Situ Hybridization (Q-FISH) based assay (Lansdorp et al., 1996). Q-FISH of telomeric repeats is 
assessed following hybridization with a fluorescent (CCCTAA)3 probe, with the remaining 
chromatin on the chromosome being visualized by a nonspecific DNA stain such as DAPI or 
propidium iodide (Krejci & Koch, 1998). Peptide Nucleic Acid (PNA) probes used in this assay 
have higher hybridization efficiency to telomeric repeats than DNA probes because of their 
neutral (uncharged) backbone (Egholm et al., 1993). Furthermore, PNA probes show increased 
thermal stability of the probe-target duplex. Despite being labor intensive and expensive, this 
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high resolution technique allows the quantification of each of the individual 92 human telomeres. 
It is also powerful in detecting chromosomes with telomere free ends (< 0.5 kb) (reviewed in 
Aubert, Hills & Lansdorp, 2012).   
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Chapter 2 
Introduction 
      Telomeres, which are crucial in maintaining genomic integrity and preventing chromosomal 
instability have been suggested to play a role in carcinogenesis (Artandi & DePinho, 2010). 
Among the different types of cancer, several studies have been conducted to investigate the 
association between telomere length and breast cancer risk (Table 1; reviewed in Zhu et al., 
2016). Breast cancer (BC) is a very heterogeneous disease, both genetically and clinically, that 
forms in tissues of the breast (Stingl & Caldas, 2007). A classification system has been 
developed in order to standardize the disease and provide insight for better treatment and 
prognosis strategies. Histologically, BC is categorized into in situ carcinoma and invasive 
carcinoma (Malhotra et al., 2010). The two main subtypes of breast carcinoma in situ are ductal 
carcinoma in situ (DCIS) (forms in tubes that carry milk to the nipple) and lobular carcinoma in 
situ (LCIS) (forms in glands that produce milk) (Malhotra et al., 2010). Invasive breast 
carcinoma forms in the ducts or lobules and spreads to other tissues of the breast, and is also 
further subdivided into invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC). 
Immunohistochemistry/FISH tests have been used to provide a molecular characterization of BC. 
Key prognostic categories that have emerged are based on the expression status of the estrogen 
(ER) receptors, progesterone (PR) receptors and/or human epidermal growth factor receptor-2 
(HER2) status (Westbrook & Stearns, 2013). Estrogen receptor (ER) positive cancer refers to BC 
in which the cells have an increased sensitivity to estrogen leading to cancer tumor growth.  
HER2 positive breast cancer has an amplification (too many copies) of the HER2 gene and/or 
increased expression of the HER2 protein, which causes the tumor to grow faster and the cancer 
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to be more aggressive. Microarray-based gene expression analyses have further identified 
molecular subtypes of BC as: basal like (ER-, PR-, and HER2-; also described as triple negative), 
luminal subtype A (ER+ and/or PR+; HER2-, + or - Ki-67), luminal subtype B (ER+ and/or 
PR+; HER2+, + or - Ki-67), and HER2 enriched (ER-, PR- and HER2+) (Perou et al., 2000, 
Sorlie et al., 2001, Sorlie et al., 2003). In addition to the prognostic value of histopathological 
classifications of BC, the identification of molecular subtypes enabled the prediction of response 
to newer targeted therapies.  
      Clinical and histopathological factors, including tumor stage, tumor size and nodal status, 
along with the growing knowledge of molecular biomarkers, have advanced the process of 
choosing effective and safe treatment options for women with BC. Surgical courses of action in 
operable tumors include breast-conserving surgery (also called lumpectomy) for early-stage BC 
or mastectomy for advanced BC (Myers, 2016). Neoadjuvant approaches (chemotherapy and 
hormonal therapy prior to surgery) for selected high-risk BC aims at shrinking the tumor size to 
potentially reducing the extent of surgery (Thompson & Moulder-Thompson, 2012). Adjuvant 
systemic therapy is a standard of care after surgery to eradicate possible micrometastatic tumor 
and lower recurrence risk in early-stage disease through the use of chemotherapy and hormonal 
therapy, whereas in advanced stage BC, it serves to control disease burden and improve survival 
(Myers, 2016). In the case of ER positive BC, which accounts for approximately 80% of BC, 
hormonal therapy is the initial treatment of choice in the form of selective estrogen receptor 
modulators (SERMs) such as tamoxifen and raloxifene or aromatase inhibitors (AIs) (Westbrook 
& Stearns, 2013). HER2 targeted therapies include trastuzumab, pertuzumab, ado-trastuzumab 
emtansine, and lapatinib. Trastuzumab, which is the most commonly used therapeutic agent for 
women with HER2+ tumors, uses a monoclonal antibody that binds to the HER2 receptor, 
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thereby suppressing cell proliferation (Giordano, Tagliabue & Pupa, 2012). Triple negative 
breast cancer is considered aggressive, with no targeted therapy available. Therefore, cytotoxic 
chemotherapy is an option offered for patients with this type of BC (Myers, 2016). There are 
several classes of cytotoxic chemotherapeutic agents, including anti-metabolites, anti-
microtubules, anthracyclines and cychlophosphamide (Westbrook & Stearns, 2013). One 
example of an anti-metabolite is capecitabine, which slows tumor growth by inhibiting DNA 
synthesis during the S phase of the cell cycle within the tumor (Parker, 2010). Among the most 
effective of the antimicrotubules treatments are the taxanes paclitaxel (taxol) and docetaxel 
(taxotere) (Westbrook & Stearns, 2013). These drugs inhibit microtubule formation, leading to 
mitotic arrest and suppression of cell growth (Fauzee, 2011). The anthracyclines doxorubicin 
(adriamycin) and epirubicin have been extensively used in the course of treatment for BC (Quiles 
et al., 2002). Several mechanisms have been proposed for doxorubicin-mediated cell death, 
including topoisomerase II poisoning, DNA adduct formation, oxidative stress and ceramide 
overproduction (Gewirtz, 1999, Minotti et al., 2004, Senchenkov, Litvak & Cabot, 2001, Yang et 
al., 2014).   
      Cancer is a leading cause of death in both more and less economically developed countries. 
In 2013, there were 14.9 million incident cancer cases worldwide. Of these, BC was the leading 
cause for cancer incidence among women, accounting for 1.8 million of those cases (Global 
Burden of Disease Cancer Collaboration, 2015). In 2016, approximately 246,660 women are 
expected to be diagnosed with BC and 40,450 deaths from BC are estimated in the United States 
(Siegel, Miller & Jemal, 2016). However, since the year 2000, BC mortality rates decreased 
significantly due to the availability of better screening tools, advanced detection strategies, and 
continually improving treatment options (Jemal et al., 2013). Although these factors have 
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increased the survival rate to at least five years in 90% of women receiving an early diagnosis, 
many cancer survivors have reported the occurrence of a number of distressing symptoms 
leading to long term effects that adversely affect their quality of life (QOL) (Jemal et al., 2009, 
Dodd et al., 2010). These symptoms, which manifest from the cancer itself or it’s treatment 
include (but are not limited to): anxiety, fatigue, depression, pain, stress, and sleep disturbances, 
which we are collectively categorizing as “psychoneurological symptoms” (PNS) (Lee at al., 
2004, Badger et al., 2007, Bardwell & Ancoli-Israel, 2008, Bower, 2008, Weinberger et al., 
2010, Satija et al., 2014, Jung et al., 2016).  PNS not only impact treatment decisions in patients 
with BC but can also challenge the cancer survivor’s ability to perform and maintain 
employment, connect with loved ones and carrying on day-to-day tasks (Hurria, Somlo & Ahles, 
2007). Although there is increased awareness to the importance of understanding the biological 
basis of PNS, the molecular mechanism(s) leading to the development and persistence of PNS 
remains inconclusive.  
      One reason patients may present with a number of symptoms, rather than a single symptom, 
is that these symptom “clusters” may share a common biological mechanism (Miaskowski & 
Aouizerat, 2007). Several studies have been conducted in order to understand the biological 
mechanism(s) underlying the development of PNS. Symptoms of cancer/cancer treatment are 
thought to be due, at least in part, to cytokine-induced sickness behavior (Cleeland et al., 2003). 
Cytokines are present in increased levels in patients with cancer (Meyers et al., 2005) and can be 
produced from tumor tissues (Sasaki et al., 2001) or in both tumor tissues and healthy cells in 
response to chemotherapy (Pusztai et al., 2004). Although cytokine-induced sickness behavior is 
considered a reasonable mechanism leading to symptom clustering in patients with cancer, it can 
not account for all the clusters reported to date; the reason being that several investigators have 
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reported different numbers of symptoms in a cluster, as well as different types of symptoms 
within a cluster (Miaskowski and Aouizerat, 2003). Several investigators have shown an 
association between each of the PNS and the activation of inflammation markers, particularly 
pro-inflammatory cytokines (reviewed in Kim et al., 2012). However, these studies have been 
limited because they focused on single symptoms and single markers of inflammation, and they 
haven’t clearly explained the mechanism leading to the development and persistence of PNS. A 
higher than expected incidence of some PNS as well as pro-inflammatory cytokines, have been 
reported prior to the initiation of chemotherapy (Meyers et al., 2005). This suggests that 
inflammation may be activated by the cancer itself, with the symptoms being worsened by 
chemotherapy. In addition, it has been suggested that some of these PNS, such as depression and 
fatigue, are actually caused by perturbations in cytokine levels acting on the brain (Dantzer et al., 
2008). However, the fact that inflammatory molecules, such as cytokines, are not retained for 
long periods of time, and the fact that these symptoms have been reported to persist in a subset of 
cancer survivors for years after therapy, led us to hypothesize that inflammation is an initiating 
step for a cascade of biological events that also include the acquisition of somatic cell genetic 
(e.g. telomere length changes; chromosomal instability) and/or epigenetic changes (e. g. 
methylation alterations), with these latter genetic/epigenetic alterations providing a means for the 
effects of the BC and/or its treatments to be maintained in one’s biological memory. 
      Acquired telomere attrition has long been speculated as a causal factor in the acquisition of 
many chronic diseases (Blackburn, Epil and Lin, 2015). Furthermore, accelerated telomere 
shortening has been shown to play a role in the pathogenesis of multiple psychological 
conditions such as, but not limited to, stress, depression and cognitive decline, all of which are 
major side effects experienced by patients with BC (reviewed in Starkweather et al., 2014). 
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Telomere shortening can be accelerated by multiple factors associated with the cancer itself or 
it’s treatment including (but not limited to) chemotherapy and oxidative damage (von Zglinicki, 
2002, Li et al., 2012). Interestingly, increased inflammatory activity can accelerate telomere 
attrition by inducing cell turnover and replicative senescence or by the release of ROSs that 
shorten and damage telomeres through oxidative stress (Aviv, 2004, Jaiswal et al., 2000). 
Induced cellular proliferation/senescence could contribute to PNS, at least in part, through 
compromised tissue homeostasis. In addition, shortening of telomeres has been associated with 
an increased frequency of chromosomal instability, which, in turn, could give rise to alterations 
in gene expression, thereby allowing the persistence of PNS. Furthermore, a reduction in the 
telomere heterochromatic region as a result of telomere attrition could alter gene expression of 
adjacent subtelomeric genes through a phenomenon known as “telomere position effect” (TPF) 
(van Deutekom et al., 1996, Baur et al., 2001, Robin et al., 2014). One can speculate that an 
epigenetic alteration in the genes juxtaposed to the telomeric region, could provide a plausible 
mechanism for the persistence of PNS into survivorship.  
      As noted earlier, telomere length alterations in patients with BC have been evaluated 
extensively as a diagnostic marker in breast tissues, but few investigators have incorporated the 
effect of chemotherapy on the telomere lengths of healthy, peripheral tissues in these patients 
(Meeker et al., 2004). However, research involving measuring telomere length in peripheral 
blood lymphocytes has been completed, with a focus on investigating the potential link between 
telomere length and the risk for developing BC or other age-related diseases (Table 1) (Heaphy 
& Meeker, 2011, Barrett et al., 2015). The results of one study on leukocytes obtained from 
patients with early stage BC showed decreased telomere length at five and nine months 
following chemotherapy when compared to baseline values (Schroder et al., 2001). However, 
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information regarding PNS was not integrated into that study since the main focus was to 
determine the effect of stem cell transplantation following chemotherapy in the evaluated group 
of patients.  
      Given that telomere shortening is accelerated by inflammation and oxidative stress, and that 
chemotherapy affects both of these processes, the primary objective of this study was to 
longitudinally evaluate telomere length in women diagnosed with early stage BC who were 
treated with chemotherapy in order to determine if chemotherapy contributes to chromatin 
breakage within the telomere, thereby leading to telomere shortening in this group of 
patients. Results from this study will allow us to test the following hypotheses: 
1.   There is a change in telomere lengths following treatment with chemotherapy in women 
diagnosed with early stage BC.  
2.   These differences in telomere lengths affect a subset of chromosomal arms rather than 
affecting all chromosomes equally. 
3.   The extent of change in telomere length differs based on the type of chemotherapy regimen 
used for treatment.  
4.   A correlation exists between telomere length changes following treatment for BC and a 
survivor’s acquisition of PNS.  
       To our knowledge, this is the first longitudinal study that provides information about 
telomere lengths over five time points, including pre-, during and post-chemotherapy treatment. 
Moreover, it is the first study to provide information about chromosome-specific telomere length 
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changes associated with chemotherapy. These expanded observations are expected to provide 
new insights in the use of peripheral blood telomere length as a biomarker for the identification 
of individuals who are sensitive to a specific type of chemotherapy and/or at higher risk for the 
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Table 1: Studies on the Association Between Telomere Length and Risk for BC  




Method  Study outcome 
Barewell et 
al. 
2007 72/1696 Leukocyte TRF TRF derived telomere 
length is not a marker for 
BC susceptibility  
Shen et al. 2007 283/347 Leukocyte qPCR Modest evidence that short 
telomere length is 
associated with increased 
breast cancer risk 
Shen et al. 2009 1026/1070 Leukocytes qPCR  Short telomere length is 
associated with breast 
cancer risk in pre-
menopausal women and 
women with low 
antioxidant dietary or 
supplementary intake 
De Vivo et 
al. 
2009 896/917 Leukocytes  qPCR No significant association 
between postmenopausal 
BC risk and short telomere 
length  
Zheng et al. 2010 293/335 Leukocytes Q-FISH Increased risk of BC with 
shorter telomere length on 




2010 102/50 Leukocytes qPCR Longer telomere length in 
women at high risk for BC 
based on family history 
Kim et al. 2011 342/735 Leukocytes qPCR No association between 
telomere length and BC risk 
Qu et al. 2013 601/695 Leukocytes qPCR Shortened telomeres is 
associated with increased 
risk of BC  
Pellatt et al. 2013 728/720 Leukocytes qPCR Longer telomere length is 
associated with increased 
BC risk  
      
Adapted from reviewed in Zhu et al., 2016. 
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Chapter 3 
Materials and Methods 
Study Participants Ascertainment  
            A total of 77 women with early stage (I to IIIA) breast cancer were ascertained through 
the Massey Cancer Center (MCC) in Virginia Commonwealth University and its multiple 
collaborative sites, including Hematology Oncology Associates of Fredericksburg, Inc., Bon 
Secours Richmond Health System, Peninsula Cancer Institute, and Rappahannock General 
Hospital. To identify potential study participants, a member of the research team attended the 
weekly interdisciplinary Breast Health meetings at Virginia Commonwealth University Health 
System (VCUHS). The eligibility criteria were: 1) an age of 21 years or older; 2) a diagnosis of 
early stage BC with a scheduled visit to receive chemotherapy; and 3) a female gender. 
Exclusion criteria were a history of: 1) a previous cancer, or chemotherapy; 2) a diagnosis of 
dementia; 3) active psychosis; or 4) immune-related diagnosis (e.g. multiple sclerosis; systemic 
lupus erythematous). From the list of patients presented at the meeting, those persons meeting 
the study inclusion criteria were identified. The study coordinator then consulted with the 
attending oncologist and with his/her approval approached the patient regarding her desires to 
participate in the study. The offsite research nurses followed similar procedures for identifying 
potential participants at his/her respective site.  
      After providing their informed consent (VCU IRB # HM 13194), all participants in this 
longitudinal study completed questionnaires and cognitive testing via a computerized system at 
each of the five time points, which were: 1) visit 1 (also referred to as “baseline”) which was 
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prior to chemotherapy; 2) visit 2 (also referred to as “mid-chemo”), which was prior to the fourth 
cycle of  chemotherapy; 3) visit 3, which was scheduled approximately 6 months following the 
initiation of chemotherapy, at which time a subset of women received radiotherapy; 4) visit 4, 
which was scheduled approximately 1 year following the initiation of chemotherapy; and 5) visit 
5, which was scheduled approximately 2 years following the initiation of chemotherapy. During 
each visit, blood samples (in green top (sodium heparin) tubes and lavender (EDTA) tubes) were 
collected by venipuncture or an existing access device and transported to the cytogenetics 
laboratory in a biohazard container. The lab staff were blinded to the clinical history and therapy 
status of the study participants at the time of sample processing and evaluation.  
Demographic, Lifestyle and Clinical Health Information 
      Demographic and lifestyle information was obtained from each study participant via self 
reporting questionnaires. The subset of the demographic data selected as most relevant for this 
current study included age, race and income. Clinical health information was obtained from 
medical records. This information included BC stage, BC grade, chemotherapy regimens and 
tumor characteristics. Tumors were characterized based on FISH and/or immunohistochemical 
testing results as luminal A (ER+ and/or PR+; HER2- ;no information was available on Ki-67), 
luminal B (ER+ and/or PR+; HER2+; no information was available on Ki-67), HER2 positive 
(ER-, PR- and HER2+) and triple negative (ER-, PR-, and HER2-) (Perou et al., 2000, Sorlie et 
al., 2001, Sorlie et al., 2003).  
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Treatment  
      Chemotherapy treatment for each study participant was administered as either: 1) Taxotere 
(docetaxel), Adriamycin (doxorubicin), and Cyclophosphamide [TAC]; 2) Taxotere and 
Cyclophosphamide [TC]; or 3) Taxotere (docetaxel), Carboplatin (paraplatin) and Herceptin 
(transtuzumab) [TCH]. Information regarding chemotherapy and radiation therapy for each 
patient was determined from medical records.   
DNA Isolation 
      Genomic DNA was extracted from whole blood using a Puregene DNA Isolation Kit 
(Qiagen) according to the manufacturers protocol. After extraction, the DNA was quantified, 
evaluated to ensure it was not degraded, and stored at -80°C. DNA stocks were diluted to 
approximately 20 ng into pure water prior to setting up qPCR runs.  
Monochrome Multiplex qPCR (MMqPCR) 
      The relative genomic telomere length was measured by monochrome multiplex real-time 
quantitative PCR (MMqPCR) as previously described, in which both the telomere and the 
housekeeping gene values are derived from the same well (Cawthon, 2009). The primer 
sequences used for this assay are shown in Table 2.  In this method, relative telomere length is 
determined as a ratio of the number of copies of the telomere repeat sequences compared to the 
copies of a single housekeeping gene (human albumin), with this number being derived from a 
standard curve. This 5-point standard curve was derived from triplicate measures on each assay 
plate. DNA for the standard curve was made from a “cocktail” of 11 healthy control women and 
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was prepared in dilutions ranging from 1.235 to 100 ng. PCR reactions were set up by aliquoting 
5 µL of 4 ng experimental DNA followed by 15 µL of SYBR Green Mastermix combined with 
telomere primer and albumin primer into each reaction well of a 96-well plate. Each plate was 
set up to include “standard DNA” in triplicate; experimental DNA in triplicate; a triplicate of a 
negative control (lacking DNA); and a triplicate of a positive control, which is DNA extracted 
from HeLa cells (known to have high T/S ratio), a normal female control age 35 cells (known to 
have medium T/S) ratio and MCF7 cells (known to have low T/S ratio). All 5 visits for each 
study participant were run on the same plate. This assured that comparisons between the five 
time points were always within the same batch, thus eliminating possible biases due to batch 
differences. An additional layer of quality control was our use of one single lot for each reagent 
for the entire study to eliminate possible batch differences due to different reagent lots.   
      Plates were run on a BioRad CFX96 with the following cycling parameters: 95oC for 5 
minutes; 2 cycles of 94oC for 15 seconds, 49oC for 15 seconds; 49 cycles of 15 seconds at 94oC, 
15 seconds at 62oC, 15 seconds at 83oC, 15 seconds at 60oC with signal acquisition, 15 seconds 
at 94oC, 20 seconds at 85oC with signal acquisition. The 60oC reads provided the the Ct values 
for the amplification of the telomere template (in early cycles when the albumin signal is still at 
baseline). The 85oC reads provided the Ct values for the amplification of albumin template at 
which time the telomere template is fully melted. BioRad CFX Manager software version 3.0 
automatically estimated the value for each T (telomere) and S (albumin single copy gene) using 
the standard curve.  
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Table 2: Primer Sequences for MMQPCR 
Site Primer Sequence 
Telomere telg: ACACTAAGGTTTGGGTTTGGGTTTGGGTTTGGGTTAGTGT 
telc: TGTTAGGTATCCCTATCCCTATCCCTATCCCTATCCCTAACA 
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Cell culture, Chromosome Harvest and Slide Preparation 
      Upon receiving the blood samples (in sodium heparin), leukocytes were isolated using 
Histopaque- 1077 (Sigma). Duplicate stimulated (using phytohemaglutinin (PHA)] lymphocyte 
cultures were established and harvested using standard procedures [RPMI 1640 media, 
supplemented with 15% Fetal bovine serum (FBS)]. Twenty minutes prior to harvesting, 
colcemid (final concentration of 0.1 µg/ml) was added in order to limit microtubule formation by 
inactivating spindle fiber formation, which arrested the cells in metaphase. Seventy-two hours 
after culture initiation, the cultures were harvested as previously described (Leach and Jackson 
Cook, 2001) using standard protocol techniques, including a 20-minute incubation in hypotonic 
solution (0.075 M KCl), a ten-minute incubation (room temperature) in fixative (3:1 methanol: 
acetic acid solution) and two additional washes in fixative. In order to reduce cytoplasm 
formation, which can compromise probe hybridization, slides were made using a Thermotron, 
which provided a constant temperature (23°C) and humidity (48 ±1°C). A phase contrast/bright 
field microscope was used to ensure that the quality of the slide preparation was optimal for the 
FISH analysis (i.e. enough metaphases present that lacked cytoplasm, had good morphology, and 
were well spread). The slides were then placed on a hot plate at 60°C for an hour, followed by 
aging at room temperature for 1-2 weeks. Alternatively, following hot plate incubation, room 
temperature aging was induced by soaking the slide in a 2xSSC solution for ten minutes prior to 
applying the FISH protocol.  
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Chromosome-Specific Telomere FISH 
      The telomere length of metaphase chromosomes was assessed using a telomere- specific 
FITC-labeled peptide nucleic acid (PNA) probe, following the manufacturer’s protocol 
(DakoCytomation, Denmark). Briefly, target slides were soaked in cold fixative (3:1 methanol: 
acitic acid) for one hour. Following air-drying, the slides were rinsed in 1xTBS (Tris-Buffered 
Saline, PH 7.5) for two minutes, fixed in 3.7% formaldehyde in 1xTBS for two minutes, and 
then rinsed twice in 1xTBS (for five minutes each time). The slides were then immersed in a pre-
treatment solution containing proteinase K for ten minutes and rinsed twice in 1xTBS for five 
minutes each. Following dehydration in an ethanol series (70%, 85% and 100%) for two minutes 
each, the slides were air-dried. After drying, 22 µl of FITC labeled PNA probe (CCCTAA)3  was 
added to each full slide and a coverslip added. Following the co-denaturation of the probe and 
metaphase chromosomes in a thermocycler at 80°C for three minutes, the slides were hybridized 
in a dry hybridization chamber at room temperature for two hours. Unbound and excess probe 
was then removed by washing in a rinse solution (provided by the manufacturer) at room 
temperature for two minutes, as well as a second wash solution (provided by the manufacture) at 
65°C for five minutes. After washing, the slides were dehydrated in a series of cold ethanol 
solutions (70%, 85% and 100%) for two minutes each. Finally, the slides were air-dried and 
counterstained with 24 µl of a 5:1 DAPI II /propidium iodide (Abott) solution.   
Telomere Image Analysis  
      A total of ten metaphases for each individual were analyzed using software on an Applied 
Imaging Cytovision system (the Comparative Genomic Hybridization (CGH) function) as 
previously described (Leach et al., 2004). Briefly, for each metaphase analyzed, three images 
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were captured using a CCD camera. The first image was captured using a DAPI filter to allow 
for subsequent karyotyping and identification of the chromosomes based on their reverse DAPI 
banding pattern. The second image was captured using a FITC filter, which allowed for the 
visualization of the telomeric probe and is termed by the software as the “test image”. The third 
image allowed for the visualization of the chromosomal body based on its propidium iodide stain 
and is termed a “reference image”. Karyograms were prepared for each metaphase spread, 
followed by the designation of the centromere and central axis for each homolog. For each 
telomere, the software compared the fluorescence intensity from the “test image” to the 
fluorescence intensity of the propidium iodide stain in the chromosomal body from the 
“reference image” to generate a ratio profile for each chromosome. For each study participant the 
intensity values were averaged over the twenty homologs from the ten metaphase spreads scored. 
Overlapping chromosomes at the telomere region were omitted from the analysis. Representative 
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Figure 1: Representative images of chromosome-specific telomere FISH. For each 
individual, 10 metaphases are analyzed and for each metaphase 3 images are captured. (A) 
Shows a metaphase spread stained with DAPI. (B) The metaphase as it appears with reverse 
DAPI bands, allowing for chromosome recognition. (C) Shows a “test image” showing telomere 
signals at the end of each chromosome arm, captured using a FITC filter. (D) Represents the 
“reference image” showing the same metaphase with a propidium iodide stain. (E) A 
representative chromosome 3 from one participant as it appears in DAPI, FITC labeled, merged 
and PI image, respectively. Also, the ratio profile of this chromosome is shown. From this profile 
(and the visual image) one can see that the short arm telomere (top of chromosome) has a larger 
fluorescence intensity value (6.63) than the long arm telomere (bottom of chromosome) (value of 
4.63).  
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Assessment of PNS  
      The following symptoms were measured by our collaborators at Virginia Commonwealth 
University School of Nursing according to the systems described: 
•  Cognitive Dysfunction  
      The CNS Vital Signs computerized neurocognitive testing system was used to measure 
cognitive dysfunction in our study participants (Gualtieri & Johnson, 2006). This system has 
been highly recommended for the use in longitudinal studies due to its high sensitivity to mild 
cognitive impairment. This system has the ability of excluding practice effects by randomly 
generating alternate test forms. Repeated measures of cognitive components with a concentration 
on memory and attention were achieved through a highly reliable and well-validated screening 
system (Gualtieri & Johnson, 2006). 
•   Stress 
      Percieved Stress Scale (PSS) is considered one of the widely used psychological 
instruments due to its well-documented reliability and validity (Cohen, Kamarck & 
Mermelstein, 1983). Participants rated how often they found their lives to be unpredictable, 
uncontrollable, and overloaded during the past month through a 10 item Percieved Stress Scale 
(PSS) (Cohen, Kamarck & Mermelstein, 1983). Each question has five possible Likert scale 
responses (never, almost never, sometimes, fairly often, and very often). Of the total responses 
on the PSS, 6 were “negative” responses and were given the following numerical value: never 
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= 0; almost never = 1; sometimes = 2; fairly often = 3; and very often = 4. The remaining 4 
positive items in the PSS were recorded in a reversed format according to standard approaches 
(i.e. never = 4…very often = 0) (Innes et al., 2012, Abut et al., 2012). All 10 response values 
were then summed to calculate the participants’ total perceived stress score, with higher scores 
indicating higher levels of perceived stress (Cohen, Kamarck & Mermelstein, 1983).  
•  Depression and Anxiety  
      The Hospital Anxiety and Depression Scale (HADS) was used to determine the presence and 
severity of depression and anxiety (Snaith, 2003). It is a questionnaire-based test where the study 
participant rated from 0-3 the severity of each symptom on 14 items over a period of 7 days. This 
assessment tool was selected for use in this study because it has been shown to have an excellent 
reliability and validity in patients with BC (Snaith, 2003).  
•   Pain  
      Pain was assessed using the Brief Pain Inventory (BPI), which is a self-reporting short 
form that is directed towards the assessment of pain severity and its impact on daily function in 
patients with pain from chronic diseases or cancer (Caraceni, 2001). Validity and reliability 
has been well established for these patients using this tool. Assessment areas include severity 
of pain, impact of pain on daily function, location of pain, pain medications and amount of 
pain relief in the past 24 hours or the past week. This test doesn’t require a scoring algorithm; 
it relies on “worst pain” or the mean of the four severity items as a measure of pain severity, 
and the arithmetic mean of the seven interference items as a measure of pain interference 
(Caraceni, 2001).  
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•   Fatigue  
      Fatigue was measured using the Brief Fatigue Inventory (BFI), which is a self-reporting test 
that is designed for patients with fatigue due to cancer and its treatment (Mendoza et al., 1999). 
This 9-item scale aids in the assessment of fatigue severity and the impact of fatigue on daily 
functioning in the past 24 hours. A global fatigue score can be obtained by averaging all the 
items on the BFI with severe fatigue being defined as a score of 7 or higher. This test has been 
used in clinical trials and has shown excellent reliability (Mendoza et al., 1999).  
•   Sleep Disturbances  
      The General Sleep Disturbance Scale (GSDS), as a means of obtaining self-reported sleep 
issues including problems initiating sleep, the number of awakenings, excessive daytime 
sleepiness and the use of medications to induce sleep over the past week (Lee, McEnany & 
Weekes, 1999). The 21 items in this tool are rated using a numeric rating scale ranging from 0 to 
7. The total score for this scale ranges from 0 (no sleep disturbance) to 147 (extreme sleep 
disturbance) and is calculated by summing the 21 items (Lee, McEnany & Weekes, 1999).  
Chromosome Instability Assessment  
      Chromosomal instability levels were quantified for each study participant using the 
cytokinesis-block micronucleus (CBMN) and cytome assay as previously described (Aboalela et 
al., 2015).   
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Statistical Analyses 
      Demographics, tumor characteristics and treatment variables in Tables 2-4 were computed 
using chi square tests for categorical data and a two sample t-test for continuous data when 
looking for differences in race (African Americans vs. Caucasian). A Pearson correlation was 
used to examine the correlation between age and telomere length, as well as between MN 
frequency and telomere length. The percent change in telomere intensity values for each 
chromosomal arm (p arm and q arm) from baseline to mid-chemo for each study participant was 
determined by the following formula: 
(Mid-chemo telomere intensity value - Baseline telomere intensity value) X 100 
Baseline telomere intensity value 
A paired t-test was used to compare mean telomere intensity values for each chromosomal arm 
between baseline and mid-chemo.  
      Using the model building approach proposed by Hosmer and Lemeshow (2000), a mixed 
effects linear model (Brown & Prescot, 2006) was fit to determine the best subset of predictors 
of qPCR-based telomere length. In the first stage of the model building process, a base model 
was selected that represented the design of data collection and the timing of treatments 
(chemotherapy and radiation). Fixed effects included, visit (baseline, mid-chemo, six months 
following the initiation of chemo, 12 months and 24 months post-chemo), chemotherapy 
regimens, visit by chemotherapy interaction (chemotherapy was administered only during visit 
2), radiation (Yes/No); visit by radiation interaction (radiation was only administered proximal to 
visit 3), and a random effect for study participants. In the second stage, each potential predictor 
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was fit individually with the base model and if the p-value was 0.25 or less, that predictor was 
used in the third stage. Potential predictors tested included demographic variables (age, race, and 
income), tumor characteristics (grade, stage, luminal A, luminal B, triple negative and HER2 
positive status) and neoadjuvant status. In the third stage, all potential regressors (p	  ≤ 0.25) were 
put into a multiple variable model. This initial model was further refined by sequentially 
removing variables from the model with the highest p-values (backward stepwise) until all 
remaining factors had a p-value of 0.05 or less. This model was considered the final prediction 
model. Least square means of significant predictor variables were tested using a Tukey test. To 
identify significant predictors of chromosome-specific telomere length, the previous base model 
was used with the exception of excluding radiation variable because chromosome-specific data 
was produced from only baseline and mid-chemo time points. In addition, instead of using a 
backward stepwise approach, each of the above mentioned potential predictors of chromosome-
specific telomere length was fit individually and was considered a significant predictor when 
having a p-value of 0.05 or less. JMP Pro 12 statistical package was used for the mixed effect 















Chapter 4  
Results  
      A total of 77 women with early stage breast cancer (I – IIIA) were recruited for this study. 
One participant provided only a baseline specimen and then withdrew from the study citing a 
“lack of time/interest” as the reason for her withdrawal. Two women failed to provide specimens 
for all five time points and explained that they had a lack of time as their reason for non-
compliance with the study protocol (96% retention rate).  Only two women received 
cyclophosphamide, methotrexate and 5 fluorouracil (CMF) treatment. Therefore, due to the small 
sample size, this subset of participants was excluded from the analysis. Telomere length 
assessment was completed for a total of 72 participants of the 77 originally enrolled in the study. 
The majority of these study participants received TAC treatment (n= 39), followed by TC (n= 
21), or TCH (n= 12).  
Demographics  
      Demographics, breast tumor characterization and treatment information for the 72 women 
participating in this longitudinal study are shown in Tables 3-5. One woman in the African 
American cohort and one woman in the Caucasian cohort self-reported being of Hispanic or 
Latino ethnicity. Given the small number of the Hispanic sub-group, these women were included 
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in the African American and Caucasian sub-groups, respectively, but the Hispanic ethnic group 
was not analyzed separately. The age of the women fully participating in the study ranged from 
23 to 71 years, with a median of 52 years. A significant difference in age was observed between 
the African American (n=22, mean = 46.6 years, standard error (s.e.) = 2.07 years) and 
Caucasian (n = 50, mean = 53.5 years, s.e. = 1.37 years) sub-groups (p = 0.007) (Table 3). 
Annual income also differed significantly between the two racial groups, with Caucasians having 
higher income than African Americans (p < 0.0001) (Table 3).  
Tumor Characteristics  
      In accordance with this study design, only women with early stage breast cancer (stages I – 
IIIA) were included. There was no significant difference in the grade of the breast cancer tumors 
present in the African American compared to Caucasian women (p = 0.197) (Table 4). Similarly, 
no significant difference was observed for the stage of breast cancer between the two racial 
groups (p = 0.055) (Table 4). While there was no significant difference in the proportion of 
tumor sub-types, there was a trend toward a higher proportion of luminal A tumors and a lower 
proportion of HER2+ and triple negative tumors in the Caucasian population (60% luminal A 
tumors; 10% luminal B tumors; 6% HER2+; 24% triple negative tumors) compared to African 
Americans (36 % luminal A; 9% luminal B tumors; 18% HER2+; 36% triple negative tumors) 
(Table 4).  
Treatment  
      The three main types of chemotherapy regimens administered to the study participants were 
categorized as 1) TAC, which included sequential administration of doxorubicin (Adriamycin), 
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cyclophosphamide (Cytoxan), and docetaxel (Taxotere); 2) TC, which included docetaxel 
(Taxotere) and cyclophosphamide (Cytoxan); and 3) TCH, which included docetaxel (Taxotere), 
Carboplatin (Paraplatin), and trastuzumab (Herceptin). No significant difference in 
neoaduvant/adjuvant status (p = 0.123), chemotherapy regimens (p = 0.291) or radiation 
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Table 3. Demographics for Study Participants Receiving Chemotherapy for Breast Cancer  
 African American 
n= 22 
 Caucasian  
n= 50 
 
 TAC           TC            TCH 
n=10           n=6           n=6 





TAC                TC            TCH 
n=29               n=15               n=6 




Age            44.0              47.0           50.5 
3.4                2.5             2.9 
     52.2                 57.1           51.0 






















1 (4%)             0                  0 
 
 

























6 (12%)        7 (14%)          3 (6%) 
 
 
















•   Number in parentheses is the percentage of participants in this category (%)  
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Table 4. Breast Tumor Characteristics in the Study Participants  




















Triple negative      
Yes  
No 
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Table 5: Treatment Characteristics in the Study Participants  
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Telomere Length Measured by MMqPCR  
      Of the total 72 women in this study, the quality of DNA from one patient did not meet 
quality control standards. Therefore, average genomic telomere lengths (which were assessed by 
the T/S ratio) were estimated for 71 study participants at all five time points using MMqPCR 
methodology. To determine if there was a potential association between telomere length at 
baseline and age, a Pearson’s correlation was calculated. As expected, based on previous studies 
showing that telomere length is inversely correlated with age in the general population, a 
significant negative correlation between the participants’ age and their average genomic telomere 
length was observed at baseline (r = -0.37, p = 0.001), as shown in Figure 2.  
      Given that telomere length has been associated with the frequency of spontaneous (and 
induced) chromosomal abnormalities in a variety of human cell types and health conditions 
(Leach et al., 2004), the T/S ratio values were compared to micronucleus/micronuclei (MN) 
frequencies (micronuclei are an indicator of chromosomal instability), at each time point using a 
Pearson correlation test. However, no significant associations were observed between mean 
telomere length and MN frequency [visit 1 T/S ratio and visit 1 MN frequency (r = -0.084, p = 
0.491); visit 2 T/S ratio and visit 2 MN frequency (r = -0.054; p = 0.659); visit 3 T/S ratio and 
visit 3 MN/ frequency (r = -0.016, p = 0.896); visit 4 T/S ratio and visit 4 M/N frequency (r = -
0.047, p = 0.708); visit 5 T/S ratio and visit 5 MN frequency (r = -0.203, p = 0.197)].     
	  
	   46	  
 
Figure 2: Association between age and average genomic telomere length at baseline. Each 
circle (•) represents a study subject. Average genomic telomere length at baseline was negatively 
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      In addition to the assessment of MN frequency, we also investigated the relationship between 
telomere length change and other treatment, demographic variables and PNS by fitting the data 
into a mixed effects linear regression model (Table 6). Potential predictive variables evaluated 
included visit, age, race, income, tumor grade and stage, receiving Herceptin, having 
neoadjuvant treatment, tumor characterization as luminal A, luminal B, triple negative or HER2 
positive and PNS including anxiety, depression, pain, fatigue, sleep disturbance and stress. The 
final optimized model identified age (p = 0.004), race (p = 0.019) and the type of chemotherapy 
treatment (p = 0.044) as having a significant predictive association with mean telomere length 
(Table 6). For the racial groups, the average genomic telomere lengths were higher in African 
American participants (mean = 1.661; s.e. = 0.087) compared to Caucasian participants (mean = 
1.420; s.e.= 0.061) (Table 6). The study visit time was not found to be a significant predictor of 
telomere length (p = 0.666). However, the shortest telomere lengths tended to be observed at 
visit 3 (p = 0.41) (where a subset of patients were on radiation treatment), with values by 12 
months and 24 months following the initiation of chemotherapy tending to be comparable to 
values at baseline (Figure 3). While visit alone was not predictive of mean telomere length, the 
type of chemotherapy used in treatment was found to be a significant predictor of telomere 
length (p = 0.044), with the subset of women receiving TAC treatment having significantly 
higher mean telomere lengths (mean = 1.681; s.e. = 0.074) than the women receiving TCH 
(mean = 1.366; s.e. = 0.103) chemotherapy regimens (p= 0.036) (table 5). However, women 
receiving TC treatment were not significantly different from TCH (p= 0.272) or TAC (p= 0.535) 
groups. Other variables screened were found to have no significant prediction of telomere length 
(Table 6).  
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Figure 3: Vlues for MMqPCR based telomere length over time. Average genomic telomere 
lengths are shown at baseline (visit 1) (mean= 1.542, s.e.= 0.062), mid-chemo (visit 2) (mean= 
1.534, s.e.= 0.070), visit 3 (mean= 1.489, s.e.= 0.064). visit 4 (mean= 1.584, s.e.= 0.068) and 
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Table 6: Mixed Effects Linear Model Fitting Assessment of Predicative Associations of 
Variables with qPCR Telomere Length 
 Base Model1              Final Model2   





Visit 0.666    




























Chemotherapy by visit 0.259    
Radiation  0.641    
Radiation by visit 0.271    
Stage  0.148    
Grade  0.954    
Herceptin Yes/No 0.857    
Neoadjuvant  0.506    
Luminal A 0.891    
Luminal B 0.529    
Triple negative  0.997    
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1 The base model, which was determined by the study design, was: telomere length = Visit + 
Chemotherapy (3 types) + Radiation therapy +Visit by chemotherapy3 + Visit by Radiation 
therapy3 with the study subject being the random effect  
2 The final model reflects variables that remained significantly associated with telomere length 
after stepwise removals  
3 The visit by chemotherapy and visit by radiation therapy variables allowed these values to 
differ across time points  
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Telomere Length Quantified Using Chromosome-Specific FISH 
      Of the 72 women included in this study, blood specimens obtained from 22 patients did not 
yield metaphases from either baseline and/or the mid-chemo specimen. Therefore, chromosome-
specific telomere lengths were compared for 50 subjects. In order to determine if there was a 
change in the telomere intensity value of each chromosomal arm (p arm and q arm) from 
baseline (visit 1) to mid-chemo (visit 2) within and across study participants, the percent change 
in telomere intensity values was calculated. Negative values reflected a decrease in telomere 
length at mid- chemo compared to baseline; a zero value reflected no change in telomere length; 
and a positive value reflected an increase in telomere length at the mid-chemo compared to 
baseline time points. The percent change values for telomeres on each chromosomal arm (short 
arm and long arm) and each study participant is graphically represented using a heat map (Figure 
4). Interestingly, while we observed that the majority of telomeres showed attrition, a small 
subset of telomeres showed increases in length as shown in Figure 5.  
      In addition to calculating percent changes, we compared telomere fluorescent intensities of 
the short and long arm of the 23 chromosomes (1-22 and X) between baseline and mid-chemo 
using a paired t-test. Significantly shortened telomeres were found on 1p (p = 0.022), 5q (p = 
0.041), 7q (p = 0.025), 9q (p = 0.045), 18q (p = 0.002), 20p (p = 0.020), 21q (p = 0.040) and 22p 
(p = 0.025), with marginal significance for decreases of telomere length being observed for 6p, 
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Figure 4: Heat map representation of percent changes in telomere intensity values from 
baseline to mid-chemo. Each column represents a chromosomal arm and each row represents a 
study participant [Study Identifier (SID)]. The legend shows the percent change, with decreases 
in telomere length represented by negative values (shown in blue tones), whereas increases in 
telomere length are represented by positive values (shown in red tones).  
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Figure 5: Mean of chromosome-specific telomere lengths in all study participants (n = 50). 
The average of the difference in telomere length from baseline to mid-chemo is shown for each 











	   54	  
 
Table 7: A Comparison of Chromosome Intensity Values Between Baseline and Mid-
Chemo Specimens in 50 Women with Early Stage Breast Cancer  
Chromosome
Mean SD Mean SD Mean of the difference p-value Mean SD Mean SD Mean of the difference p-value
1 4.085 1.702 3.556 1.767 -0.529 0.022 5.292 2.058 4.955 2.228 -0.337 0.272
2 5.291 2.148 4.787 2.184 -0.504 0.102 4.084 1.732 3.718 1.793 -0.366 0.155
3 6.054 2.128 5.579 2.233 -0.475 0.144 5.148 2.238 4.714 2.108 -0.434 0.158
4 4.349 1.903 3.947 1.856 -0.402 0.160 5.588 2.155 5.204 2.173 -0.384 0.195
5 5.107 2.074 4.749 2.072 -0.358 0.241 4.811 2.135 4.186 2.029 -0.625 0.041
6 5.452 2.171 4.866 2.118 -0.586 0.084 5.180 2.119 4.614 2.134 -0.566 0.069
7 4.419 1.868 3.935 1.763 -0.484 0.058 5.182 2.107 4.449 2.058 -0.733 0.025
8 5.222 2.017 4.663 1.970 -0.559 0.054 4.396 1.993 4.052 2.105 -0.344 0.198
9 5.429 2.080 4.879 2.142 -0.550 0.062 3.781 1.768 3.322 1.731 -0.459 0.045
10 5.326 2.117 4.967 2.188 -0.359 0.228 4.621 2.004 4.170 1.935 -0.451 0.093
11 4.587 1.897 4.204 1.994 -0.383 0.173 5.123 2.110 4.693 2.201 -0.430 0.134
12 4.636 1.909 4.194 2.093 -0.442 0.145 4.659 1.958 4.216 2.009 -0.443 0.142
13 4.858 1.963 4.340 1.999 -0.518 0.064 5.331 2.202 4.809 2.164 -0.522 0.090
14 4.827 2.069 4.432 2.256 -0.395 0.165 4.754 2.135 4.275 1.952 -0.479 0.069
15 4.544 1.969 4.208 1.976 -0.336 0.218 5.193 2.117 4.737 2.170 -0.456 0.111
16 3.920 1.796 3.484 1.590 -0.436 0.119 4.305 1.869 3.938 1.955 -0.367 0.167
17 4.106 1.765 3.717 1.714 -0.389 0.150 4.118 1.815 3.714 1.782 -0.404 0.099
18 5.188 2.141 4.596 2.056 -0.592 0.051 5.496 2.098 4.620 1.877 -0.876 0.002
19 3.997 1.791 3.631 1.686 -0.366 0.149 4.580 1.887 4.135 1.901 -0.445 0.135
20 4.979 2.060 4.282 1.977 -0.697 0.020 4.187 1.805 3.743 1.949 -0.444 0.134
21 5.060 2.124 4.543 1.955 -0.517 0.108 4.413 1.867 3.897 1.740 -0.516 0.040
22 4.902 2.016 4.239 1.949 -0.663 0.025 4.058 1.795 3.610 1.827 -0.448 0.090
X 5.240 2.103 4.893 2.149 -0.347 0.236 4.850 2.075 4.589 2.199 -0.261 0.385
                                         Short Arm                                                  Long Arm
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      In agreement with the paired t-test results, a mixed effects model adjusted for age showed 
that there is a significant shortening in chromosome-specific telomere length from baseline to 
mid-chemo on chromosomal arms 1p (p = 0.022), 5q (p = 0.041), 7q (p = 0.025), 9q (p = 0.045), 
18q (p = 0.002), 20p (p = 0.020), 21q (p = 0.040) and 22p (p = 0.025) (Table 8).  
      To further assess the association between chemotherapy treatment on telomere lengths, a 
fixed effects model, adjusted for age, was also fit to the chromosome-specific data. The type of 
chemotherapy treatment was observed to be predictive of telomere lengths on 32 of the 46 
chromosomal arms (Table 9), with participants receiving TAC chemotherapy treatment have 
numerically higher mean telomere lengths on those chromosomes compared to study participants 
receiving TC or TCH treatment (Table 9).  
      To determine if there was an association between telomere length and PNS we included 
“total” values for the symptoms of anxiety, depression, pain, fatigue, sleep disturbance and stress 
into the mixed effect model, adjusted for age, to assess their predictive potential of chromosome-
specific telomere length. Among all the PNS tested, pain (but no other symptoms) was found to 
be a significant negative predictor of telomere lengths (higher pain; shorter telomeres) for 5q (p 
= 0.040), 8p (p = 0.047), 13p (p = 0.019), 20p (p = 0.036), 22p (p = 0.035), Xp (p = 0.014), Xq 
(p = 0.039) (Table 10). 
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Table 8: Mixed Effects Linear Model Fitting Assessment of Visit as a Significant 
Predicative variable of Chromosome-Specific Telomere Length  
Chromosome Arm   Least Square 
Mean at Baseline 





        1p 3.632 3.103 0.264 0.022 
5q    4.428 3.803 0.330 0.041 
7q    4.757 4.024 0.331 0.025 
9q    3.376 2.917 0.217 0.045 
18q    5.078 4.204 0.311 0.002 
20p    4.635 3.938 0.320 0.020 
21q    3.954 3.438 0.274 0.040 
22p    4.499 3.835 0.305 0.025 
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Table 9: Mixed Effects Linear Regression Model Fitting Assessment of Predictive 
Association of Chemotherapy Type with Chromosome-Specific Telomere Length  
Chromosome 
Arm 
TAC Least Square 
Mean  
TC Least Square 
Mean  
TCH Least Square 
Mean  
P-value  
1p 4.346 (0.251) 2.944 (0.451) 2.813 (0.501) 0.004 
1q 5.642 (0.314) 4.016 (0.564) 4.433 (0.626) 0.028 
2p  5.602 (0.315) 3.929 (0.565) 4.174 (0.628) 0.017 
2q  4.247 (0.263) 3.125 (0.473) 3.486 (0.526) 0.094 
3p  6.252 (0.319) 4.671 (0.574) 5.508 (0.637) 0.059 
3q 5.488 (0.317) 3.853 (0.570) 4.051 (0.634) 0.020 
4p  4.475 (0.280) 3.671 (0.502) 3.436 (0.558) 0.157 
4q  5.876 (0.326) 4.425 (0.586) 4.689 (0.651) 0.059 
5p 5.451 (0.295) 3.696 (0.531) 4.376 (0.589) 0.014 
5q  4.590 (0.309) 3.682 (0.556) 3.714 (0.618) 0.064 
6p 5.698 (0.298) 4.028 (0.536) 4.417 (0.596) 0.015 
6q 5.383 (0.312) 3.835 (0.561) 4.279 (0.623) 0.039 
7p 4.598 (0.269) 3.465 (0.484) 3.383 (0.538) 0.043 
7q 5.335 (0.305) 3.673 (0.549) 4.163 (0.609) 0.022 
8p 5.453 (0.288) 3.821(0.518) 4.301 (0.575) 0.016 
8q  4.685 (0.312) 3.252 (0.561) 3.593 (0.623) 0.056 
9p 5.664 (0.314) 4.201 (0.564)  4.304 (0.627) 0.034 
9q 4.037 (0.259) 2.581 (0.465) 2.821 (0.517) 0.012 
10p  5.729 (0.313) 4.114 (0.562) 4.107 (0.624) 0.013 
10q  4.821 (0.299) 3.726 (0.537) 3.531 (0.597) 0.070 
11p  4.791 (0.292) 3.639 (0.524) 3.758 (0.582) 0.090 
11q 5.413 (0.327) 4.152 (0.587) 3.837 (0.653) 0.045 
12p 4.890 (0.287) 3.289 (0.515) 3.918 (0.572) 0.023 
12q  4.838 (0.289) 3.674 (0.520) 3.791 (0.578) 0.083 
13p 5.093 (0.289) 3.422 (0.519) 4.096 (0.576) 0.018 
13q 5.599 (0.323) 4.146 (0.580) 4.111 (0.645) 0.033 
14p 5.221 (0.314) 3.349 (0.565) 3.864 (0.628) 0.010 
	  
	   58	  
14q 5.000 (0.312) 3.487 (0.561) 3.856 (0.623) 0.041 
15p 4.885 (0.285) 3.131 (0.512) 3.896 (0.569) 0.012 
15q 5.535 (0.318) 3.823 (0.571) 4.112 (0.634) 0.017 
16p 4.064 (0.237) 2.993 (0.426) 3.137 (0.473) 0.049 
16q  4.614 (0.281) 3.126 (0.504) 3.398 (0.560) 0.020 
17p  4.282 (0.250) 3.083 (0.449) 4.464 (0.499) 0.051 
17q  4.265 (0.276) 3.126 (0.496) 3.507 (0.551) 0.110 
18p  5.224 (0.322) 4.218 (0.578) 4.404 (0.643) 0.238 
18q 5.556 (0.292) 4.058 (0.526) 4.310 (0.584) 0.024 
19p 4.281 (0.248) 2.280 (0.445) 3.185 (0.495) 0.010 
19q 4.852 (0.261) 3.232 (0.469) 3.786 (0.522) 0.009 
20p  5.054 (0.300) 3.684 (0.539) 4.122 (0.599) 0.067 
20q  4.430 (0.262) 2.917 (0.470) 3.414 (0.522) 0.015 
21p  5.356 (0.278) 3.474 (0.500) 4.242 (0.555) 0.005 
21q 4.700 (0.257) 3.121 (0.462) 3.267 (0.513) 0.004 
22p 5.068 (0.282) 3.438 (0.506) 3.995 (0.562) 0.016 
22q 4.269 (0.264) 3.086 (0.475) 3.028 (0.527) 0.031 
Xp  5.518 (0.322) 4.320 (0.579) 4.190 (0.643) 0.077 
Xq 5.237 (0.316) 3.834 (0.567) 3.756 (0.630) 0.032 
     
*  The standard error is shown in parenthesis  
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Table 10: Pain as a Significant Negative Predictor of Telomere Length   









1q -0.196 0.124 0.121 
2p -0.127 0.126 0.319 
2q -0.146 0.105 0.170 
3p -0.185 0.127 0.151 









5p -0.188 0.117 0.115 
5q -0.120 0.120 0.040 
6p -0.131 0.120 0.279 
6q -0.222 0.122 0.076 
7p -0.197 0.105 0.069 
7q -0.119 0.123 0.335 
8p -0.229 0.112 0.047 
8q -0.195 0.123 0.122 
9p -0.242 0.122 0.054 
9q -0.164 0.102 0.116 
10p -0.199 0.124 0.114 
10q -0.202 0.118 0.093 
11p -0.177 0.116 0.133 
11q -0.203 0.129 0.123 
12p -0.175 0.113 0.130 
12q -0.215 0.113 0.064 
13p -0.267 0.110 0.019 
13q -0.197 0.128 0.131 
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14p -0.158 0.126 0.215 
14q -0.189 0.124 0.133 
15p -0.186 0.112 0.106 
15q -0.216 0.125 0.090 
16p -0.168 0.093 0.077 
16q -0.204 0.110 0.070 
17p -0.164 0.099 0.103 
17q -0.212 0.108 0.055 
18p -0.252 0.125 0.051 
18q -0.181 0.116 0.124 
19p -0.145 0.098 0.148 
19q -0.187 0.102 0.075 
20p -0.251 0.116 0.036 
20q -0.126 0.105 0.235 
21p -0.185 0.110 0.099 
21q -0.139 0.102 0.180 
22p -0.237 0.109 0.035 
22q -0.189 0.103 0.075 
Xp -0.311 0.122 0.014 
Xq -0.260 0.122 0.039 
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Chapter 5  
Discussion  
      In this study we sought to measure telomere length in lymphocytes obtained from patients 
who received chemotherapy for breast cancer using two different, but complementary, telomere 
length assays. The first was a qPCR-based assay, which is considered a high throughput assay 
with fast turn-around time that allows for the estimation of average genomic telomere length. 
The second assay used was a chromosome-specific PNA-FISH assay, which allows for the 
quantification of telomere lengths on each chromosomal arm, as well as the mean genomic 
telomere length. The use of both assays provided a confirmatory opportunity for the results 
discussed herein.  
      Consistent with the results of other investigators (Svenson et al., 2008, Wang et al., 2011), 
baseline telomere lengths of the women in our study showed a significant inverse correlation 
with age (older women had shorter telomeres). Furthermore, age was found to be a significant 
predictor of telomere length in our study cohort. Telomere attrition is one of the several cellular 
and molecular hallmarks contributing to the aging process and arises as a result of the end 
replication problem (reviewed in Aubert & Lansdorp, 2008, Lopez-Otin et al., 2016). It is 
thought that environmental and life-style related factors, such as smoking, exposure to pollution, 
lower physical activity, psychological stress, and unhealthy diet also contribute to accelerating 
telomere shortening and the ageing process via increased levels of inflammation and oxidative 
burden (von Zglinicki, 2000, Cherkas et al., 2008, Cassidy et al., 2010, Barrett et al., 2015, 
reviewed in Zhang et al., 2016). Furthermore, the sequence motif in human telomeres 
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(TTAGGG), which have a triple guanine structure, is thought to make them particularly 
susceptible to oxidative damage, with the repair of this oxidative damage being relatively 
inefficient (Kawanishi, Hiraku & Oikawa, 2001, von Zglinicki, 2002).  
      Another demographic variable that was observed to be a significant predictor of mean 
telomere length in our study cohort was race, with African Americans having longer mean 
telomere lengths than Caucasians. This observation has been reported in other studies 
investigating the relationship of race with telomere length in families with high and low risk of 
cardiovascular disease (Hunt et al., 2008), as well as healthy individuals (Lynch et al., 2016). 
Interestingly, in a case-control study on the association between leukocyte telomere length and 
breast cancer risk, Zheng, et al. (2010) reported higher mean telomere lengths in African 
Americans compared with Caucasians in newly diagnosed, pretreatment cases with breast 
cancer, but not in matching controls (Zheng et al., 2010). The mechanism(s) underlying this 
racial difference in telomere length is/are not well understood. One reason might be that healthy 
African Americans were found to have lower oxidative damage levels and lower plasma levels of 
antioxidants than Caucasians, suggesting that there might be race-related differences in the 
cellular processes involved in oxidative-related DNA damage and repair (Huang, Helzlsouer, 
&Appel, 2000, Watters et al., 2007, Watters, Satia, & Kupper, 2008). Alternatively, although the 
mixed effect model used in this study allowed adjusting for age, the inter-relatedness of human 
epidemiology variables increases the possibility for the presence of an effect from other 
confounding factors. Thus, one cannot fully rule out the possibility that the age distribution in 
our study cohort may have contributed to this association with race since the African American 
participants were significantly younger than the Caucasians (Aboalela, et al., 2015). Moreover, 
our model was not adjusted for other potential confounding factors that have been demonstrated 
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to be associated with higher oxidative stress or short telomere length, including (but not limited 
to) body mass index (BMI), smoking status, alcohol consumption, physical activity and the 
intake of antioxidants (Watters, Satia, & Kupper, 2008, Muezzinler, Zaineddin, & Brenner, 2013, 
Muezzinler et al., 2015, Muezzinler et al., 2016).  
      The main aim of this study was to test our hypothesis that chemotherapy contributes to 
chromatin breakage within the telomere, thereby leading to telomere shortening in women with 
early stage breast cancer. Using the data from the qPCR-based method, we did not observe a 
significant change in mean telomere lengths across the 5 time points in this 2-year longitudinal 
study. Although telomere length in epidemiological studies is most often evaluated as a single 
mean genomic measure, investigators have shown that there is heterogeneity between 
chromosomes (and between individuals) for telomere length, as well as variability between 
telomeric arms (short arm compared to long arm) within a chromosome (Lansdorp et al., 1996, 
Hemann et al., 2001, Gilson & Londono-Vallejo, 2007, Xu et al., 2013). Moreover, the results of 
a number of reports have suggested that telomere shortening does not occur at an equal rate 
among all chromosomal arms and that chromosomal arms with the shortest telomeres are most 
frequently involved in end-to-end fusions and genomic instability (Hemann et al., 2001, Soler et 
al., 2005). However, the qPCR-based mean telomere length assay cannot fully detect 
chromosome-specific heterogeneity (e.g. presence of relatively long telomeres could mask the 
presence of a sub-set of short telomeres present on specific chromosomal arms), nor can it 
capture information about telomeres that are extremely short/missing. Therefore, given the above 
mentioned limitations of the qPCR methodology, we elected to also measure chromosome-
specific telomere lengths.  
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      By exploiting the strength of our longitudinal study design for this chromosome-specific 
comparison, we were able to quantify changes in telomere length within a study subject (thereby 
reducing the impact of person-to-person variations in telomere lengths). The results of this 
analysis showed significant telomere attrition for a subset of 8 different chromosomal arms; 
specifically, 1p, 5q, 7q, 9q, 18q, 20p, 21q, and 22p. There are very few investigators who have 
evaluated chromosome-specific telomere lengths as they relate to cancer, with these few studies 
being concentrated on the relationship between chromosome-specific length and the risk of 
acquiring breast cancer or esophageal cancer (Table 11) (Zheng et al., 2009, Xing et al., 2009, 
Zheng et al., 2011). Therefore, our observation is considered an initiating step for investigating 
possible mechanisms responsible for these chromosomes to be preferably shortened during/after 
treatment for breast cancer.  
     Two main factors that have been conjectured to drive telomere length shortening, beside the 
end replication problem, are inflammation and oxidative DNA damage (von Zglinicki, 2002). 
Our observation that the type of chemotherapy received was predictive of telomere length is 
consistent with these canonical influences. There are several potential mechanisms that could 
explain our observed association between chemotherapy and telomere length. Genotoxic drugs 
may have an intrinsic role in telomere shortening given that telomeres have been shown to be 
particularly susceptible to oxidative damage and since repair of this damage is relatively 
inefficient in telomeres (von Zglinicki, 2000, von Zglinicki 2002, Shen et al., 2009, Fumagalli et 
al., 2012).   
      In addition to exerting their therapeutic effect through direct DNA damage, chemotherapeutic 
drugs that are frequently used in treating breast cancer have an indirect negative impact on 
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telomeres by affecting members of the shelterin complex. Among the six shelterin components, 
TRF2 and POT1 were found to be the most important in ensuring chromosome end protection by 
preventing ATM and ATR dependent checkpoint activation (van Steensel, Smogorzewska, & de 
Lange, 1999, Karlseder et al., 1999, Denchi & de Lange, 2007, Guo et al., 2007). Moreover, 
doxorubicin has been found to reduce the expression of POT1 and TPP1, which in turn could 
alter the telomere structure and compromise its stability, thereby promoting telomere shortening 
(Li et al., 2012, Kato et al., 2013).  
     Another class of chemotherapeutic drugs frequently used in treating breast cancer is Taxanes, 
which act through mitotic inhibition (Janssen & Medema, 2011). Although the exact mechanism 
for the induction of cell death upon mitotic inhibition is unknown, it is proposed that prolonged 
mitotic inhibition, in vitro, has the ability to dissociate TRF2 from telomeres and activate a DNA 
damage response, thereby providing a mechanism for telomere shortening through telomere 
dysfunction. (Hayashi et al., 2012, Lu et al., 2013).  
      In addition to showing that overall chemotherapy was predictive of telomere length, we also 
showed that there were differential effects based on the type of chemotherapy used in treatment, 
with telomere lengths of women receiving TAC regimens being significantly different from 
those receiving TCH regimens. Adriamycin (also known as doxorubicin) is a member of the 
anthracycline class of chemotherapeutic agents. Anthracyclines are thought to shorten telomeres 
through direct DNA damage by free radical formation (von Zglinicki, 2000, Quiles et al., 2002, 
Thorn et al., 2011). Another proposed mechanism of action for anthracyclines is the inhibition of 
DNA repair enzymes, particularly topoisomerase II, which may contribute to telomere 
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shortening through further accumulation of DNA damage (Table 12) (Elmore et al., 2002, 
Maccormick, 2006, Thorn et al., 2011, Buttiglieri, et al., 2011).  
       While a subset of women receiving TAC had shortened telomeres, we also observed the 
unexpected result that overall patients on the TAC regimen had longer mean telomere lengths 
when compared to patients undertaking TCH regimens. Similarly, the model used for the 
analysis of the chromosome-specific telomere data showed that patients on the TAC regimen had 
numerically higher telomere lengths than patients undertaking TC or TCH. One of the key 
components to the TAC regimen that is not present in the TCH regimen is the presence (or 
absence) of Adriamycin, which has been shown to have several cytotoxic effects and has been 
associated with telomere shortening, as noted above. When coupling the knowledge of the 
cellular effects of Adriamycin with our study results, they initially seemed to be paradoxical. 
However, a plausible explanation could be that ALT is activated as a rescue mechanism of the 
extensive DNA damage caused by TAC. From experiments on immortalized human cell lines 
that utilize the ALT mechanism for telomere length maintenance, it is hypothesized that ALT 
involves homologous-recombination (HR) mediated DNA copying of telomeric DNA (Dunham 
et al., 2000, Conomos, Picket & Reddel, 2013). One can speculate that telomeres become 
uncapped due to excessive shortening; presumably because they are no longer able to bind 
sufficient shelterin proteins (Denchi & de Lange, 2007, Sfeir & de Lange, 2012). Given the role 
of TRF2 and POT1 in suppressing HR-mediated DNA damage repair (Rai et al., 2016), it is 
reasonable to speculate that depletion of both proteins as an effect of Adriamycin would allow 
the activation of ALT through HR-mediated DNA repair.  
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      One of the fundamental questions addressed in this study was the association between 
telomere length and PNS in patients treated for early stage BC. While no statistically significant 
associations between PNS and overall mean telomere length (using a qPCR method) were 
observed, our chromosome-specific telomere length data indicated that pain is a significant 
negative predictor of the length of the telomeres localized to 5q, 8p, 13p, 20p, 22p, Xp and Xq. 
Standard medical interventions of breast cancer (i.e., surgery, chemotherapy and/or radiotherapy) 
have pain as a common consequence (Starkweather, Lyon, & Schubert, 2011, Ferreira et al., 
2015). The relationship between proinflammatory cytokines, including (but not limited to) CRP; 
TNFα; IL-2; IL-6; IL-8; IL-10, and pain has been established in many clinical conditions 
associated with inflammation, with higher levels of these inflammation markers being associated 
with greater pain intensity/sensitivity (reviewed in DeVon et al., 2014). Excessive telomere 
shortening arising as a result of oxidative stress mediated by increased inflammatory activity 
from the cancer itself, or chemotherapy, may lead to increased replicative senescence. Given that 
lymphocytes with shortened telomeres and senescent cells hypersecrete proinflammatory 
cytokines, particularly IL-6 (Efross, 2009), accelerated telomere attrition may play a role in the 
development of pain in our study cohort by contributing to the increased levels of IL-6. 
Furthermore, since chronic pain represents a physiological stressor, the associated increase in 
pro-inflammatory cytokines, upon activation of the stress pathway, may also be considered as a 
potential pathway for increased telomere shortening, thereby creating a cycle of telomere 
shortening from high levels of inflammation and increased pain sensation from increased 
telomere attrition-mediated cellular senescence.  
     Given that IL-6 molecules are not retained for a long period of time, the above proposed 
mechanisms may be an initiating step, with telomere biology playing a role in the persistence of 
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pain in patients with breast cancer into survivorship. However, the nature of the association 
between pain and telomere length is not clear. It is possible that this relationship is merely 
correlative, with the telomere length serving as a “canary in a coal mine” type observation that 
enables one to document that a biologically relevant change has occurred. Alternatively, it has 
been speculated that telomere length shortening could initiate epigenetic changes in genes that, in 
turn, contribute to acquired phenotypes. These epigenetic changes could arise as a result of the 
telomere position effect (TPE), which involves the spreading of a heterochromatic conformation 
of the DNA juxtaposed to the telomere to silence subtelomeric genes, with this phenomenon 
functioning in relation to telomere length. In a study of a complex-age associated disease, 
facioscapulohumeral muscular dystrophy (FSHD), TPE was shown to extend at least 100 kb into 
the subtelomeric region of chromosome 4q where the gene that is linked to the disease is up-
regulated by an effect of telomere shortening (Stadler et al., 2013). While the biological cascade 
of events is not known, one could speculate that a change in the chromatin structure of the 
subtelomeric region driven by telomere attrition in any of the chromosomal arms identified in 
this study could alter gene expression thereby contributing to the “biological remembering” of 
PNS.   
      The quantification of (MN) frequencies in lymphocytes of patients with cancer has been used 
extensively as a biomarker of chromosomal damage and genomic instability. Being part of a 
larger study, we had access to MN frequencies scored in lymphocytes obtained from our study 
cohort at the five time points, as indicated earlier. Given that telomeric attrition has been 
associated with an increased frequency of chromosomal stability, we expected to see a negative 
correlation between telomere length and micronuclei frequency (shorter telomeres leading to 
higher MN levels). While negative relationships were observed between these variables, the 
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correlations did not reach significance at the five time points tested. It is quite feasible that while 
aberrations related to telomeric attrition following chemotherapy may arise, the majority of 
chromosomal changes being induced by chemotherapy may occur at sites other than the 
telomere, thereby reducing the association between telomere length and MN frequency.  
      Another variable lacking a significant predictive association with telomere length in our 
study cohort is the tumor characteristics. Shorter telomeres in tumor tissue have been associated 
with more aggressive subtypes, including luminal B, HER2 positive and triple negative tumors 
(Heaphy et al., 2011), but little is known about the association of a patient’s leukocyte telomere 
length based on her breast tumor molecular sub-group characterization. In a recent study, 
Barczak, et al (2016) reported shorter telomere lengths in leukocytes derived from patients with 
higher stage breast cancer compared to patients at an early stage of the disease, but found no 
association between the histological cancer grade and leukocyte telomere length in patients with 
early or advanced stage breast cancer. In this study, we also did not find tumor stage, or tumor 
molecular sub-groups, to be predictive of lymphocyte telomere length. However, it is reasonable 
to conjecture this lack of association between telomere length and tumor characteristics could be 
due to the inclusion of only women with early stage breast cancer. Alternatively, leukocyte 
telomere length may not be predictive of tumor telomere lengths. 
      The most prominent strength of our study is its longitudinal design that allowed for the 
assessment of telomere length prior to chemotherapy, during active treatments and into 
survivorship. Moreover, most studies on telomere dynamics are limited by focusing on 
measuring average genomic telomere length using qPCR-based methodology. Our use of the 
chromosome-specific assay enabled us to assess individual telomeres. However, this later assay 
	  
	   70	  
is very labor intensive and expensive therefore, our assessment of telomere length using this 
method was limited to only baseline and mid-chemo, which in turn limited our comparisons to 
only two time points. Also, since high quality metaphases for the chromosome-specific assay, 
could not be obtained from a subset of our study participants, the sample size was decreased for 
this assay. Another limitation of this study was that our statistical analysis did not adjust the 
mixed effect models for all possible confounders. Therefore, our observations may have been 
affected by these confounders.  
      In summary, we showed that demographic factors significantly associated with telomere 
shortening were age and race. Using our chromosome-specific assay, we also showed that 
overall, telomere length in lymphocytes obtained from women treated for breast cancer is 
shortened following the initiation of chemotherapy treatment and that the change in telomere 
length (from baseline values) differs based on the type of chemotherapy used in treatment. We 
also demonstrated that this shortening doesn’t affect all telomeres equally, with telomeres on 
only a subset of chromosomal arms being most impacted. Lastly, our study showed that pain was 
significantly related to telomere shortening in this study cohort.  
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Table 11: Chromosome-Specific Telomere Length and Cancer Risk  
Reference  Study Sample Method Summary of Finding  
Zheng et al., 2009 Cases: 153 women with 
breast cancer who have not 
been treated with 
chemotherapy or 
radiotherapy  
Controls: 159 age matched 
healthy women  
Q-FISH Short telomere on 
chromosome 9p is 
strongly associate with 
breast cancer risk  
Zheng et al., 2011 Cases: 204 women with 
breast cancer who have not 
been treated with 
chemotherapy or 
radiotherapy  
Controls: 236 age matched 
healthy women 
PNA-FISH Short telomere length on 
chromosomes 9p,15p, 15q  
and Xp is associated with 
breast cancer risk in pre-
menopausal women  
Xing et al., 2009 Cases: 94 untreated 
patients with esophageal 
cancer  
Controls: 94 age, gender 
and ethnicity matched 
healthy subjects 
STELA Short telomere length on 
chromosomes 17p and 
12q play a more 
prominent role in the 
etiology of esophageal 
cancer than 11q and 2p 
     
Q-FISH= Quantitative Fluorescence In Situ Hybridization  
PNA-FISH= Peptide Nucleic Acid Fluorescence In Situ Hybridization 
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Table 12: Studies on the Effect of Doxorubicin (Adriamycin) on Telomere Biology  
Reference Sample type Study outcome 
Elmore et 
al., 2002 
Mcf7 breast tumor cell line  Breast tumor cells treated with Adriamycin 
require both functional p53 and telomere 




LiSa-2 ALT positive cell line derived 
from a poorly differentiated 
pleomorphic liposarcoma 
LS2 cell line derived from ALT-
positive pleomorphic liposarcoma 
SW872 cell line expressing expressing 
both components of telomerase  
Cell lines sensitivity to doxorubicin correlated to 
topoisomerase 2A (TOP2A) gene expression, with 
LiSa-2 cell line showing the highest sensitivity to 
doxorubicin and the highest expression of TOP2A 
followed by LS2 cell line 
SW872 cell line showed showed the lowest 
sensitivity to doxorubicin and the lowest 




Mesenchymal stem cells derived from 
normal human bone marrow  
Telomere loss following treatment with 
doxorubicin that was also associated with defects 
in proliferation and differentiation  
Li et al., 
2012 
T-lymphocytes isolated from buffy 
coats of healthy individuals with 
stimulated telomerase activation 
Normal human lung fetal fibroblasts 
representing telomerase deficient cells 
Rapid loss of telomeric DNA sequence, coupled 
with down-regulation of telomerase activity, 
repression of hTERT, TPP1 and POT1 (members 
of the shelterin complex) expression in T-
lymphocytes and fibroblasts treated with 
doxorubicin resulting in telomere dysfunction in a 
high fraction of cells 
Kato et 
al., 2013 
Human cervical carcinoma cell line 
(HeLa), human normal fibroblast cell 
line (WI-38), human osteosarcoma cell 
lines (U-2-OS and Saos-2) 
TRF1 and POT1 (members of the shelterin 
complex) mRNA levels were commonly down-
regulated in both cancerous and normal cell lines 
following treatment with doxorubicin. On the 
other hand, RAP1 was up-regulated in a time-
dependent manner in 2-OS cells only   
Sanoff et 
al., 2014 
33 women with early stage breast 
cancer (I-III) who were receiving 
doxorubicin, cychlophosmaide and 
taxane  
Telomere length was measured before 
chemotherapy and 12 months after chemotherapy, 
with no significant change observed  
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Chapter 6  
Conclusion and Future Directions  
Concluding Remarks 
      Telomere biology plays a critical role in regulating cellular life span, aging and genomic 
instability. Therefore, telomere length has emerged as a prominent molecular marker of adverse 
health outcomes, such as breast cancer, which is among the most prevalent diseases worldwide 
but also one that has a high survival rate because of continuous advancements in detection and 
treatment strategies. Telomere length alterations in patients with breast cancer have been 
evaluated extensively as a diagnostic marker in breast tissue. However, research involving 
measuring telomere length in peripheral blood lymphocytes have focused primarily on 
investigating the potential link between telomere length and the risk of developing breast cancer. 
Clearly, there is a lack in the literature for studies investigating the relationship between genetic 
changes, particularly telomere attrition and the development and persistence of PNS under the 
influence of chemotherapy in patients with breast cancer.    
Future Directions   
      This work was designed to assess telomere length in women with early stage breast cancer 
who were treated with chemotherapy, with the goal of improving our understanding of the role 
biological events play in the development and persistence of PNS. We have successfully 
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identified significant shortening in telomere length following the administration of chemotherapy 
in specific chromosomal arms. Furthermore, we have identified that patients in our study cohort 
having shorter telomere length on particular chromosomal arms reported higher pain intensity. 
Mammalian telomeric regions are enriched in signatures of heterochromatin including 
hypermethylation (Benetti, Garcia-Cao & Blasco, 2007). The heterochromatic signature of the 
telomeric region induces a position effect by spreading into the subtelomeric region as a function 
of length (Robin et al., 2014). We therefore, suspect that chromosomes showing significant 
telomere shortening may have an altered methylation profile in the subtelomeric region. This 
may in turn change the expression of genes associated with PNS if present. As mentioned earlier, 
this study is part of a larger study in which genome-wide methylation patterns were assessed 
using the 450K HumanMethylation Chip at baseline and mid-chemo time points. The 
methylation data could be used to determine if the distribution of sites showing methylation 
alterations from baseline to mid-chemo are more heavily localized to the subtelomeric regions of 
the telomeres that were showing significant shortening or the telomeres associated with pain. A 
change in the cell’s methylation pattern(s) could have changed the expression of genes 
associated with pain, thereby allowing the biological remembering of this side effect into 
survivorship. Thus, we have already initiated additional studies to evaluate the possible presence 
of a relationship between methylation patterns and telomere length in this study cohort. 
      Interestingly, although not significant, a subset of our participants showed both shortening 
and lengthening of telomeres. This caught our attention as to what mechanism was responsible 
for this observation? The absence or insufficient amount of telomerase in adult somatic cells, 
points toward ALT as a plausible mechanism for increases in telomere lengths in our cohort. 
Support for this hypothesis is derived from the proposed effect of chemotherapeutic drugs on 
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different members of the shelterin complex which in turn could facilitate ALT through HR 
mediated DNA repair. To further investigate this hypothesis, we intend to determine ALT status 
by checking for the presence of telomere-sister chromatid exchange (T-SCE), which can be 
detected using chromosome-orientation Fluorescence In Situ Hybridization (CO-FISH) on 
metaphase spreads obtained from the study participants. This technique involves culturing cells 
for a single replication cycle with the incorporation of the thymidine analog 5-bromo-2’-
deoxyuridine (BrdU) for it’s incorporation into the newly synthesized DNA strand and 
subsequent destruction through nuclease digestion. This leaves the template strand intact for 
FISH with telomere strand probes that can indicate the occurrence of a recombination event 
between sister chromatids (Bailey et al., 2001, Vera et al., 2008). Furthermore, the presence of 
telomere lengthening shown in our results could be also be addressed by determining the 
existence of associations between telomere length and different healthy life style behaviors (such 
as consuming a healthy diet, regular physical activity, practicing meditation), which have been 
associated with longer telomere lengths in several studies. Careful analysis of these variable that 
were obtained from our study cohort could aid in teasing apart the telomere lengthening 
observation.  
      The influence of inflammatory markers and oxidative stress on telomere length and their 
close association with PNS could provide another direction for expanding upon this study. 
Increased cell turnover and replicative senescence negatively affect telomere length. Gene 
expression levels of a classical marker of cellular senescence, CDKN2A (also known as p16), 
IL-6 and IL-8, as well as measures of a wide range of proinflammatory cytokines, including IL-
6, were obtained from our study cohort. Therefore, our future studies will involve investigating 
the potential correlation between these variables and telomere length would provide a plausible 
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explanation for the observed telomere shortening in lymphocytes of patients with early stage 
breast cancer.  
      To the best of our knowledge, this is the first study to provide insights into the effect of 
chemotherapy on telomere length and their relationship with adverse side effects experienced in 
patients with breast cancer over a period of 2 years. If confirmed and expanded upon in future 
studies, these observations would be important for the recognition of lymphocyte telomere length 
as a biomarker for the identification of women who are at an increased risk of developing PNS 
and potentially designing therapeutic and intervention strategies that will be most effective in 
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